What is Thymalin and how is it produced?

Thymalin is a polypeptide complex extracted from the thymus glands of calves. It contains a mixture of low-molecular-weight peptides (predominantly di-, tri-, and tetrapeptides) that are believed to replicate the immunoregulatory functions of endogenous thymic factors. It was developed by Russian scientists Vladimir Khavinson and Vyacheslav Morozov in the 1970s and has been used clinically in Russia since 1977.

Is Thymalin approved for medical use?

Thymalin is registered and available for clinical use in Russia and some former Soviet states. However, it is not approved by the MHRA, EMA, FDA, or any other Western regulatory authority. The clinical evidence supporting its use consists primarily of Russian-language publications and observational studies that do not meet the methodological standards required for Western regulatory approval.

How does Thymalin relate to Epitalon?

Both Thymalin and Epitalon were developed by Professor Vladimir Khavinson as part of his peptide bioregulation programme. Thymalin targets the thymus gland and immune function, whilst Epitalon targets the pineal gland and is researched for telomerase activation and circadian rhythm regulation. Khavinson's most-cited study examined their combined use over 15 years in elderly patients, reporting reduced mortality. They are conceptually complementary but act through different mechanisms.

What is thymic involution and why does it matter?

Thymic involution is the progressive shrinkage of the thymus gland that begins around puberty and continues throughout life. By age 50, thymic tissue is largely replaced by fatty tissue, dramatically reducing the production of new naive T-cells. This decline in thymic output contributes to immunosenescence — the age-related weakening of immune function. Thymalin is proposed to partially compensate for this decline by providing thymic peptide factors exogenously.

Is Thymalin safe to use?

Thymalin has been used in Russian clinical practice for over 40 years with reports of a generally favourable safety profile. However, it is an animal-derived biological product, which carries inherent risks including allergic reactions. Furthermore, the lack of Western-standard pharmacovigilance data means the full safety profile is not well characterised by international standards. Use should only be considered under medical supervision.

Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 13 March 2026

Share:X Post LinkedIn

Immune & Inflammatory•Updated 2026-03-13•8 min read

What Is Thymalin? Benefits, Research & Safety

A polypeptide complex extracted from the thymus gland, researched for immune system regulation, T-cell maturation, and potential anti-ageing effects through restoration of thymic function.

Share:X Post LinkedIn

Also known as:

Thymic Factor

Thymus Peptide Extract

Timalin

DAnimal/cell evidence onlyUK: Sold as 'research only' (UK)WADA: Sport status unclear

UK summary: Not a licensed UK medicine. A multi-peptide thymic extract developed by the Russian Khavinson group; used clinically in Russia since the late 1970s. Independent Western replication is limited; UK access is research-only.

Quick Facts

Overview

Thymalin is a polypeptide complex originally isolated from the thymus glands of calves. Developed in the 1970s by Russian scientists Professor Vladimir Khavinson and Professor Vyacheslav Morozov at the Saint Petersburg Institute of Bioregulation and Gerontology, Thymalin represents one of the earliest examples of bioregulatory peptide therapy — the concept that short peptides can restore age-related decline in organ function. The thymus gland plays a central role in adaptive immunity, serving as the site where T-lymphocytes (T-cells) mature and undergo selection. However, the thymus undergoes progressive involution (shrinkage) beginning in puberty, with a corresponding decline in thymic output of naive T-cells. This thymic involution is believed to contribute to immunosenescence — the age-related deterioration of immune function that increases susceptibility to infections, cancer, and autoimmune conditions in older individuals. Thymalin is composed of a mixture of low-molecular-weight peptides derived from thymic tissue, with the predominant active components believed to be dipeptides and tripeptides that interact with immune cell differentiation and maturation pathways. The preparation has been registered and used clinically in Russia for several decades as an immunomodulator, though it has not been approved by Western regulatory authorities. Khavinson's broader research programme has explored the concept that organ-specific peptide bioregulators can restore function in ageing tissues. Thymalin's partner compound, Epitalon (epithalamin), targets the pineal gland and has been studied for its effects on telomerase activation and circadian regulation. Together, these compounds form the basis of "peptide bioregulation" theory. Thymalin is not approved for therapeutic use by the MHRA, EMA, or FDA. It has been used clinically in Russia but its evidence base does not meet Western regulatory standards. All information here is for educational purposes.

Evidence standards summary

Thymalin — evidence and risk at a glance

Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.

01Evidence snapshot

DAnimal/cell evidence onlyOverall grade against our evidence grading methodology.

Not a licensed UK medicine. A multi-peptide thymic extract developed by the Russian Khavinson group; used clinically in Russia since the late 1970s. Independent Western replication is limited; UK access is research-only.

02Human evidence grade

DAnimal/cell evidence onlyStrength of evidence from published human trials.

03Preclinical evidence grade

CLimited human evidenceAnimal-model and in-vitro evidence quality.

04Regulatory status

UK: Not licensed by the MHRA for any indication. Not available through standard healthcare channels.
EU: Not authorised by the EMA. Not recognised as an approved medicinal product in EU member states.
Notes: Thymalin has been registered and used clinically in Russia since 1977 and is available in several former Soviet states. However, the evidence base consists primarily of Russian-language publications and observational studies that do not meet Western regulatory standards for approval. Western pharmaceutical development would require Phase I–III trials conducted under Good Clinical Practice (GCP) guidelines. Products available online are unregulated and may vary in quality, purity, and authenticity.

05Approved medical uses

None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)

06Unapproved / promotional claims

Reverses thymic involution and restores youthful immunity.
Extends human lifespan when paired with Epitalon.
Cures chronic infections, autoimmune disease, and post-viral syndromes.
Safe long-term injectable anti-ageing therapy.

07Common internet claims

Marketed in 'Russian longevity protocol' stacks alongside Epitalon.
Sold by online retailers as research-only injectable thymic peptide.
Promoted by some private 'anti-ageing' clinics for immune restoration.

08Claim vs evidence

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Reverses age-related immune decline”	D	Limited	High	Russian observational and small-trial data suggest immunoregulatory effects; independent confirmation is limited; not a UK-licensed treatment.
“Safe long-term anti-ageing protocol”	E	No	High	Long-term human safety in healthy adults is not established.

09Safety uncertainty score

High

Limited human safety data; meaningful uncertainty about rare or long-term effects.

10Known adverse signals

Russian-jurisdiction clinical use reports good short-term tolerability.
Theoretical risk of triggering autoimmune flares with immune stimulation.
Caution required in transplant recipients.
Sterility and identity of grey-market product unverified outside Russia.

11Drug-interaction uncertainty

High

Interaction picture sparse; meaningful uncertainty when combined with other medicines.

12Anti-doping status

WADA: Sport status unclearWADA strict-liability framing applies.

13UK legal position

UK: Sold as 'research only' (UK)

Not licensed by the MHRA for any indication. Not available through standard healthcare channels.

Read the full UK legal guide → Research peptides and UK law

14EU legal position

Not authorised by the EMA. Not recognised as an approved medicinal product in EU member states.

15What this page cannot tell you

Whether a UK-purchased vial contains thymic-peptide extract at the labelled concentration.
Whether the Russian-jurisdiction trial evidence would meet UK NICE thresholds.
Long-term safety in non-Russian populations.
How it interacts with immunosuppressants or biologics.

16Last reviewed

Last reviewed: 13 March 2026

Next review due: 13 March 2027

Spotted an error or something out of date? Send a correction.

17Citation quality score

DAnimal/cell evidence onlyQuality of the sources we cite, graded against the evidence grading methodology.

18Research gaps

Independent Western Phase 3 trials absent.
Mechanism characterisation incomplete; preparation is a multi-peptide extract, not a defined molecule.
Long-term outcomes data sparse outside Russian sources.
Comparative-effectiveness data versus Thymosin Alpha-1 absent.

19Safer alternatives / established care pathways

GP and immunology referral for genuine immune-deficiency or recurrent-infection concerns.
Standard vaccination programmes — the highest-evidence immune intervention available.
NHS chronic-infection / autoimmune specialist pathways for diagnosed conditions.

20Doctor discussion prompts

Questions to ask a qualified clinician

These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

Is Thymalin a licensed UK medicine?
What licensed approaches to immune health are appropriate?

Discovery & History

Thymalin was developed in the early 1970s by Vladimir Khavinson and Vyacheslav Morozov, then young military physicians at the Kirov Military Medical Academy in Leningrad (now Saint Petersburg), Russia. Their work was part of a broader Soviet research programme investigating bioregulatory peptides — small peptides extracted from various organs that were hypothesised to regulate the function of the tissues from which they were derived. The concept was rooted in the observation that the thymus gland, despite its involution with age, continues to produce peptide factors that influence immune cell development. Khavinson and Morozov developed methods to extract and partially purify these peptide fractions from calf thymus tissue, creating a preparation they named Thymalin (Тималин in Russian). Initial clinical studies in the 1970s and 1980s focused on immunodeficiency states, including post-surgical immune suppression, recurrent infections, and immune dysfunction in elderly patients. The results, published primarily in Russian-language journals, reported improvements in T-cell counts, immune function markers, and clinical outcomes. In 1977, Thymalin was registered for clinical use in the Soviet Union, making it one of the earliest peptide bioregulators to achieve regulatory approval anywhere in the world. It has since been used in Russia and several former Soviet states for various immunodeficiency conditions. Throughout the 1990s and 2000s, Khavinson expanded the bioregulatory peptide concept, developing preparations from multiple organs and eventually identifying specific short peptides (di-, tri-, and tetrapeptides) that he proposed as the active components. His institute conducted a landmark 15-year observational study in elderly patients treated with Thymalin and Epitalon, reporting significant reductions in mortality compared to control groups. Khavinson's work has been prolific — he holds numerous patents and has published extensively. However, the research has faced criticism regarding methodology, lack of double-blind placebo-controlled trials meeting Western standards, and the predominance of publications in Russian-language or lower-impact journals.

Mechanism of Action

Thymalin's proposed mechanisms of action relate to its mimicry of endogenous thymic peptide factors and their effects on immune regulation: **T-Cell Maturation and Differentiation** The thymus gland produces several peptide factors (including thymulin, thymopoietin, and thymosin fractions) that guide the maturation of T-lymphocyte precursors into functional T-cells. Thymalin is proposed to supplement these declining thymic factors, thereby: - Promoting the differentiation of immature thymocytes into functional CD4+ helper T-cells and CD8+ cytotoxic T-cells - Supporting the thymic selection process that eliminates self-reactive T-cells (central tolerance) - Enhancing the output of naive T-cells with diverse receptor repertoires **Immunomodulatory Effects** Rather than simply stimulating immune function, Thymalin appears to act as a modulator — capable of both enhancing suppressed immunity and tempering overactive immune responses: - Restoration of T-helper to T-suppressor cell ratios toward normal values - Enhanced natural killer (NK) cell activity - Modulation of cytokine production profiles - Normalisation of immunoglobulin levels **Neuroendocrine-Immune Interactions** Khavinson's research has proposed that Thymalin interacts with the neuroendocrine system, potentially: - Modulating melatonin secretion through thymus-pineal axis interactions - Influencing cortisol and stress hormone levels - Affecting the hypothalamic-pituitary-thymic regulatory circuit **Gene Expression and Epigenetic Effects** More recent research from Khavinson's group has proposed that short peptides, including those in Thymalin, can penetrate cell nuclei and interact directly with DNA, influencing gene expression. Specifically: - Binding to specific promoter regions of genes involved in immune regulation - Modulation of chromatin condensation affecting gene accessibility - Potential effects on DNA methylation patterns These claims regarding direct DNA interaction are among the more controversial aspects of Khavinson's work and require further independent validation. **Antioxidant and Cytoprotective Effects** Thymalin preparations have demonstrated antioxidant properties in some studies, potentially through: - Enhancement of endogenous antioxidant enzyme systems - Reduction of lipid peroxidation markers - Protection of immune cells from oxidative damage

Researched Benefits

Based on preclinical and clinical research findings:

1
Restoration of T-cell counts and T-helper/T-suppressor ratios in immunodeficient patients in Russian clinical studies
2
Reduced incidence of respiratory infections in elderly patients in observational studies
3
Enhanced natural killer cell activity reported in multiple Russian publications
4
Reported mortality reduction in a 15-year observational study when combined with Epitalon in elderly patients
5
Normalisation of immune function markers following surgery, radiation, or chemotherapy in Russian clinical practice
6
Potential anti-ageing effects through restoration of thymic function and immune competence
7
Improved vaccine responses in elderly individuals in limited studies
8
Modulation of inflammatory markers in chronic disease states

Claim vs Evidence

How popular claims about Thymalin stack up against the current research, graded using our public evidence grading methodology.

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Reverses age-related immune decline”	D	Limited	High	Russian observational and small-trial data suggest immunoregulatory effects; independent confirmation is limited; not a UK-licensed treatment.
“Safe long-term anti-ageing protocol”	E	No	High	Long-term human safety in healthy adults is not established.

Theoretical Dosing & Protocols

⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.

Theoretical Dosage	5–10 mg per injection (based on Russian clinical protocols)
Frequency	Daily for 5–10 consecutive days, with courses repeated 1–3 times annually
Duration	Short courses (5–10 days) repeated periodically; continuous long-term use not typically employed
Notes	These protocols are derived from Russian clinical practice where Thymalin has regulatory approval. They have not been validated in Western-standard randomised controlled trials. Thymalin is not approved by the MHRA, EMA, or FDA. The preparation quality and standardisation may vary significantly between sources. Always consult a qualified healthcare professional.

Administration Routes

Routes studied in research settings (educational only):

Intramuscular injection (standard route in Russian clinical practice)
Subcutaneous injection (alternative route)

Half-Life	Stability
Not precisely characterised in published literature; effects of a single course are reported to persist for several months, suggesting biological effects beyond direct peptide activity	Lyophilised powder stored at 2–8°C; reconstituted solution should be used promptly; as a natural peptide extract, batch-to-batch consistency may vary

Safety Profile & Known Risks

Commonly Reported Side Effects

Injection site reactions (pain, redness, swelling)
Mild allergic reactions (theoretical risk with any biological extract)
Transient fatigue during initial treatment days
Mild flu-like symptoms (potentially reflecting immune activation)

Rare Risks & Concerns

Allergic or anaphylactic reactions (risk with animal-derived biological products)
Theoretical risk of immune dysregulation if used inappropriately
Unknown long-term risks due to lack of Western-standard clinical trials
Potential for prion or infectious agent transmission from animal-derived preparations (theoretical)
Unpredictable effects in patients with autoimmune conditions

Contraindications

Known allergy to animal-derived proteins or peptide preparations
Active autoimmune diseases (may exacerbate immune-mediated tissue damage)
Pregnancy and breastfeeding (no safety data available)
Organ transplant recipients on immunosuppressive therapy (potential for graft rejection)
Active malignancies — effects on tumour immunity are unpredictable
Children (limited safety data outside Russian studies)

UK & EU Regulatory Context

🇬🇧 United Kingdom

Not licensed by the MHRA for any indication. Not available through standard healthcare channels.

🇪🇺 European Union

Not authorised by the EMA. Not recognised as an approved medicinal product in EU member states.

Thymalin has been registered and used clinically in Russia since 1977 and is available in several former Soviet states. However, the evidence base consists primarily of Russian-language publications and observational studies that do not meet Western regulatory standards for approval. Western pharmaceutical development would require Phase I–III trials conducted under Good Clinical Practice (GCP) guidelines. Products available online are unregulated and may vary in quality, purity, and authenticity.

Clinical Studies Summary

Peptides of pineal gland and thymus prolong human life.

The obtained data confirmed the high geroprotective efficacy of Thymalin and Epithalamin and the expediency of their application in medicine and social care for health maintenance and age-related pathology prevention in persons over 60 to prolong their active longevity.

Neuro Endocrinol Lett. 2003View on PubMed

Chrono- and Immunocorrection of Inflammatory Disorders of Internal Reproductive Organs in Women of Reproductive Age.

In the groups of women receiving ridostin or thymalin during the reaction of lymphocyte SDH to it, improvement of clinical laboratory and immunological parameters was observed in the majority of the patients and no effect was found in a lesser group of patients than in the groups treated with drugs during the absence of lymphocyte SDH reaction thereto.

Bull Exp Biol Med. 2015View on PubMed

Chornobyl catastrophe: cytogenetic effects of low dose ionizing radiation and their modification.

The results of our studies have shown that such substances as thymalin, inosine, ascorbic acid, caffeine could modify radiation-induced cytogenetic effects in peripheral blood lymphocytes of healthy individuals and exert protective or sensitizing action dependent on their concentrations, cell radiosensitivity, dose of irradiation, and relative biologic effectiveness of ionizing radiation.

Exp Oncol. 2016View on PubMed

[Characteristics of the pineal gland and thymus relationship in aging].

Analysis of these data showed that pineal peptides (Epithalamin, Epitalon) had more effective geroprotective effect on thymus involution in comparison with geroprotective effect of thymic peptides (Thymalin, Thymogen) on involution of pineal gland. The key mechanisms of pineal peptides effect on thymus dystrophy is immunoendocrine cooperation, which is realized as transcription's activation of various proteins.

Adv Gerontol. 2011View on PubMed

[Influence of peptides from pineal gland on thymus function at aging].

Analysis of these data showed that pineal peptides (epithalamin, epitalon) had more effective geroprotective effect on thymus involution in comparison with geroprotective effect of thymic peptides (thymalin, thymogen) on involution of pineal gland. The key mechanisms of pineal peptides effect on thymus dystrophy is immunoendocrine cooperation, which is realized as transcription's activation of various proteins.

Adv Gerontol. 2010View on PubMed

Peptides and Ageing.

According this theory, ageing is an evolutionary determined biological process of changes in gene expression resulting in impaired synthesis of regulatory and tissue-specific peptides in organs and tissues, which provokes their structural and functional changes and the development of diseases.

Neuro Endocrinol Lett. 2002View on PubMed

Looking for Thymalin?

Source research-grade Thymalin from a trusted UK supplier — third-party tested with certificate of analysis.

View at Supplier

Frequently Asked Questions

Questions to ask a qualified clinician about Thymalin